Rituximab Combined With Chemotherapy in Burkitt's Lymphoma

Sponsor
PETHEMA Foundation
Study ID
NCT00388193
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this clinical trial is to prove the efficacy of the following new regimen treatment: * Administration of anti-CD20 (Rituximab) combined with chemotherapy. * Combined treatment with high doses of methotrexate and high doses of cytarabine with conventional cytostatics (block C) * Prophylactic administration of G-CSF after all chemotherapy cycles * local irradiation after 6 cycle if CNS was affected or if there are residual tumour

Key Dates

Start date
Aug 31, 2006
Status verified
Feb 2013
Primary completion
Dec 31, 2013
Completion
Dec 31, 2013

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Determinate the efficacy of the administration of anti-CD20 (RITUXIMAB) combined with chemotherapy. [ Time Frame: 1 year ]

Related Studies